| Stephanie Robinson, ARNP | |
|
1790 Blairs Ferry Rd, Hiawatha, IA 52233-2033 | |
| (319) 378-8362 | |
| Not Available |
| Full Name | Stephanie Robinson |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 16 Years |
| Location | 1790 Blairs Ferry Rd, Hiawatha, Iowa |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1811141765 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | A106118 (Iowa) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mercy Medical Center - Cedar Rapids | Cedar rapids, IA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mercy Physician Associates Inc | 1355242496 | 91 |
| Mercycare Management, Inc | 2466343363 | 36 |
News Archive
Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that the U.S. Food and Drug Administration (FDA) has notified CTI that a Prescription Drug User Fee Act (PDUFA) action date of April 23, 2010 under standard review has been established regarding CTI's NDA for pixantrone as potential treatment for relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL).
World-class standards for clinical outcomes and patient safety are at the core of a landmark affiliation agreement signed today between Johns Hopkins Medicine International (JHI) and Pac-fico S.A. Entidad Prestadora de Salud (Pac-fico Salud), a Lima, Peru-based subsidiary of Credicorp Ltd.
To control the three-dimensional shape of engineered tissue, researchers grow cells on tiny, sponge-like scaffolds. These devices can be implanted into patients or used in the lab to study tissue responses to potential drugs.
Shire plc announces that the U.S. Food and Drug Administration has approved Xiidra (lifitegrast ophthalmic solution) 5%, a twice-daily eye drop solution indicated for the treatment of the signs and symptoms of dry eye disease in adult patients.
› Verified 2 days ago
| Entity Name | Mercy Physician Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427254952 PECOS PAC ID: 1355242496 Enrollment ID: O20040120000805 |
News Archive
Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that the U.S. Food and Drug Administration (FDA) has notified CTI that a Prescription Drug User Fee Act (PDUFA) action date of April 23, 2010 under standard review has been established regarding CTI's NDA for pixantrone as potential treatment for relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL).
World-class standards for clinical outcomes and patient safety are at the core of a landmark affiliation agreement signed today between Johns Hopkins Medicine International (JHI) and Pac-fico S.A. Entidad Prestadora de Salud (Pac-fico Salud), a Lima, Peru-based subsidiary of Credicorp Ltd.
To control the three-dimensional shape of engineered tissue, researchers grow cells on tiny, sponge-like scaffolds. These devices can be implanted into patients or used in the lab to study tissue responses to potential drugs.
Shire plc announces that the U.S. Food and Drug Administration has approved Xiidra (lifitegrast ophthalmic solution) 5%, a twice-daily eye drop solution indicated for the treatment of the signs and symptoms of dry eye disease in adult patients.
› Verified 2 days ago
| Entity Name | Mercycare Management, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467659268 PECOS PAC ID: 2466343363 Enrollment ID: O20040322000692 |
News Archive
Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that the U.S. Food and Drug Administration (FDA) has notified CTI that a Prescription Drug User Fee Act (PDUFA) action date of April 23, 2010 under standard review has been established regarding CTI's NDA for pixantrone as potential treatment for relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL).
World-class standards for clinical outcomes and patient safety are at the core of a landmark affiliation agreement signed today between Johns Hopkins Medicine International (JHI) and Pac-fico S.A. Entidad Prestadora de Salud (Pac-fico Salud), a Lima, Peru-based subsidiary of Credicorp Ltd.
To control the three-dimensional shape of engineered tissue, researchers grow cells on tiny, sponge-like scaffolds. These devices can be implanted into patients or used in the lab to study tissue responses to potential drugs.
Shire plc announces that the U.S. Food and Drug Administration has approved Xiidra (lifitegrast ophthalmic solution) 5%, a twice-daily eye drop solution indicated for the treatment of the signs and symptoms of dry eye disease in adult patients.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Stephanie Robinson, ARNP Po Box 1824, Cedar Rapids, IA 52406-1824 Ph: (319) 369-4605 | Stephanie Robinson, ARNP 1790 Blairs Ferry Rd, Hiawatha, IA 52233-2033 Ph: (319) 378-8362 |
News Archive
Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that the U.S. Food and Drug Administration (FDA) has notified CTI that a Prescription Drug User Fee Act (PDUFA) action date of April 23, 2010 under standard review has been established regarding CTI's NDA for pixantrone as potential treatment for relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL).
World-class standards for clinical outcomes and patient safety are at the core of a landmark affiliation agreement signed today between Johns Hopkins Medicine International (JHI) and Pac-fico S.A. Entidad Prestadora de Salud (Pac-fico Salud), a Lima, Peru-based subsidiary of Credicorp Ltd.
To control the three-dimensional shape of engineered tissue, researchers grow cells on tiny, sponge-like scaffolds. These devices can be implanted into patients or used in the lab to study tissue responses to potential drugs.
Shire plc announces that the U.S. Food and Drug Administration has approved Xiidra (lifitegrast ophthalmic solution) 5%, a twice-daily eye drop solution indicated for the treatment of the signs and symptoms of dry eye disease in adult patients.
› Verified 2 days ago
Jessica L Deblois, ARNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1001 N Center Point Rd Ste C, Hiawatha, IA 52233 Phone: 319-362-0200 Fax: 319-399-5186 | |
Dr. Kassiani Alexandra Kelleher, DNP, ARNP, PMHNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1340 Blairs Ferry Rd, Hiawatha, IA 52233 Phone: 319-398-6575 | |
Stephanie B Gray, DNP, ARNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1731 Boyson Rd, Hiawatha, IA 52233 Phone: 319-363-0033 Fax: 319-363-4411 | |
Vanessa Solomon, ARNP, FNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1940 Blairs Ferry Rd Ste 104, Hiawatha, IA 52233 Phone: 319-393-0178 | |
Emily C Fitzpatrick, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1001 N Center Point Rd Ste C, Hiawatha, IA 52233 Phone: 319-362-0200 Fax: 319-375-6199 | |
Laura B Lipsett, ARNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 400 South Blairsferry Crossing, Suite B, Hiawatha, IA 52233 Phone: 319-368-5950 | |
Barbara Jean Roth, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1340 Blairs Ferry Rd, Hiawatha, IA 52233 Phone: 319-398-6575 |